Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib (Q27853105)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib	scientific article

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib (English)

1 reference

PubMed publication ID

13 November 2016

15

0 references

Marlous Hoogstraat

1

0 references

Marijn van Stralen

object named as

Marijn van Stralen

7

0 references

13

object named as

Daniel S Peeper

0 references

author name string

Christa G Gadellaa-van Hooijdonk

2

0 references

Inge Ubink

3

0 references

Nicolle J M Besselink

4

0 references

Mark Pieterse

5

0 references

Wouter Veldhuis

6

0 references

Eelco F J Meijer

8

0 references

Stefan M Willems

9

0 references

Michael A Hadders

10

0 references

Thomas Kuilman

11

0 references

Oscar Krijgsman

12

0 references

Marco J Koudijs

14

0 references

Emile E Voest

16

0 references

Martijn P Lolkema

17

0 references

publication date

May 2015

0 references

Pigment Cell & Melanoma Research

0 references

28

0 references

3

0 references

318-23

0 references

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The patterns and dynamics of genomic instability in metastatic pancreatic cancer

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

MEK1 mutations confer resistance to MEK and B-RAF inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Semi-automatic software increases CT measurement accuracy but not response classification of colorectal liver metastases after chemotherapy.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Tumor adaptation and resistance to RAF inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact.

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Tumor volume as an alternative response measurement for imatinib treated GIST patients

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identification of genetic disparity between primary and metastatic melanoma in human patients

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12347

21 January 2018

Identifiers

10.1111/PCMR.12347

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

PubMed publication ID

13 November 2016

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853105&oldid=1878795093"